AGO2 encodes Argonaute-2, the catalytic component of the microRNA-induced silencing complex (miRISC). Unlike other Argonaute proteins, AGO2 possesses endonuclease (slicing) activity that can directly cleave perfectly complementary mRNA targets. AGO2 is essential for miRNA-mediated gene silencing and has been implicated in various neurological disorders including Alzheimer's disease, Parkinson's disease, and ALS. This page covers AGO2 structure, function, disease associations, and therapeutic potential. [@coyle1995]
Overview
Mermaid diagram (expand to render)
Structure and Mechanism
Domain Architecture
AGO2 contains the same domain structure as other Ago proteins:
N-terminal domain: Mediates interactions and target recognition
PAZ domain: Binds 3' end of miRNA
MID domain: Binds 5' phosphate of miRNA
PIWI domain: Catalytic center with RNase H-like fold
The critical difference is that AGO2 has an intact catalytic DEDH tetrad (Asp-Asp-Glu-His) in its PIWI domain, enabling it to cleave (slice) perfectly matched targets.
Slicing Activity
AGO2 is the only catalytically active human Argonaute:
Can directly cleave perfectly complementary mRNA targets
This "slicing" activity leads to mRNA degradation
Required for some miRNA-mediated silencing pathways
Normal Physiological Functions
miRNA-Mediated Silencing
AGO2 is central to miRNA function:
Primary mediator of miRNA-guided mRNA cleavage
Also mediates translational repression
Essential for development and cellular function
Synaptic Function
In [neurons](/entities/neurons):
Regulates local protein synthesis at synapses
Controls dendritic spine morphology
Important for synaptic plasticity
Brain Development
AGO2 is essential for:
Neuronal differentiation
Axon guidance
Cortical development
Disease Associations
Alzheimer's Disease
AGO2 in AD:
Dysregulated in AD brain
Regulates [APP](/entities/app-protein) and [BACE1](/entities/bace1) expression
Affected by AD-associated stress responses
Some variants modify AD risk
Parkinson's Disease
In PD:
Regulates [LRRK2](/entities/lrrk2) and [α-synuclein](/proteins/alpha-synuclein) expression
Dysregulated miRNA-AGO2 pathways in PD
May influence dopaminergic neuron survival
ALS
In ALS:
AGO2 is sequestered into stress granules in ALS
[TDP-43](/mechanisms/tdp-43-proteinopathy) pathology affects AGO2 function
Dysregulation contributes to motor neuron degeneration
Cancer
AGO2 is frequently upregulated in cancers:
Promotes tumor progression
Enhances cell proliferation
Regulates oncogenes and tumor suppressors
Expression
Key Publications
[He et al., Argonaute proteins in neurodegeneration (2024)](https://doi.org/10.1016/j.tins.2024.03.002)
[Huang et al., AGO2 in Alzheimer's disease (2021)](https://doi.org/10.1186/s13024-021-00444-5)
[Gasri-Plotnitsky et al., Argonaute and ALS (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.06.001)
Therapeutic Potential
AGO2 is a therapeutic target:
siRNA delivery: AGO2 is exploited for therapeutic gene silencing
miRNA modulators: miRNA mimics/antagomirs affect AGO2 function
Small molecules: Modulate miRISC loading
Gene therapy: Deliver specific miRNAs targeting disease genes
Cross-References
[AGO1](/genes/ago1) — Argonaute-1
[DICER1](/genes/dicer1) — MicroRNA processing
[TARDBP](/genes/tardbp) — TDP-43
[FUS](/entities/fus) — FUS protein
[MicroRNA](/entities/microrna) — Small non-coding RNAs
[Synaptic Plasticity](/mechanisms/synaptic-plasticity) — Synaptic function
[Alzheimer's Disease](/diseases/alzheimers-disease) — AD mechanisms